involved in complex traits. A recent review article makes this point and goes on to show that, surprisingly, the rate of discovery of disease genes has actually decreased since the genome was completed, even though positional cloning and positional candidate genetics are easier than ever before (Antonarakis and Beckmann, 2006) . Part of the reason is that funding agencies and, presumably, a good number of peer reviewers regard rare mendelian traits as easy to solve and not worthy of funding. The fact of the matter is that most disease genes, including many involved in complex traits or cancer, have emerged from monogenic disorders. For example, the patched gene was identified by study of the very rare Gorlin syndrome but is a major player in basal-cell carcinoma, the most common human cancer. We accept that filaggrin is an unusual example of the genre, and we agree that a large-scale approach to complex traits is required, but we would suggest that a more balanced view be taken, as so much of what we know about basic genetic mechanisms underlying both common and rare disorders continues to come from the mendelian camp.
Our work on filaggrin has firmly established an important role of the keratinocyte and the epidermal barrier formation in atopic dermatitis. As the epidermal differentiation complex locus on 1q21 is also known to harbor a psoriasis susceptibility gene (Bowcock and Cookson, 2004) , we posit that a barrier defect is also involved in this complex trait. Furthermore, an autosomal dominant form of the follicular occlusion disorder hidradenitis suppurativa was recently linked to a large interval containing the epidermal differentiation complex (Gao et al., 2006) . Thus, the importance of maintaining a sound barrier in the skin and its appendages may come to the fore in genodermatology in the near future. Palmer Ten years ago the phrase "epidermal differentiation complex" (EDC) was first coined in this journal to describe the 1.6-Mb locus on human chromosome 1q21 that contains more than 30 genes encoding both epidermal cornification and S100 proteins (Mischke et al., 1996) . Now, finally, the EDC has revealed one of its most guarded secrets: Resident in this gene complex is the cause of the very common skin disorder ichthyosis vulgaris (IV) (OMIM 146700). In a recent report in Nature Genetics, Smith, McLean, and colleagues have convincingly demonstrated that mutations in the gene encoding filaggrin (FLG), the keratin filament-aggregating protein, underlie IV (Smith et al., 2006) . Twenty years ago, a defect in the synthesis of FLG was observed in IV patients (Sybert et al., 1985) . Four years ago, genetic linkage between the EDC and a sub-phenotype of IV was confirmed (Compton et al., 2002) . So why did it require a tour de force genetic study, harnessing all of the resources of the human genome project, to prove that mutations in FLG protein underlie IV?
The answer to this question lies in the unique genetic and genomic structure of the EDC, which will also be discussed in this Commentary. IV is characterized by fine white scale over the lower abdomen, arms, and legs. Palmar hyperlinearity and keratosis pilaris are also commonly associated with IV. Typically, patients have normal skin as infants, and the disease manifests within the first year. IV is often exacerbated by dry, cold climates and improved in warm, humid environments. A classic study in 1966 examined 6,051 healthy English schoolchildren and determined that one in 250 was affected with IV (Wells and Kerr, 1966) . Initial genetic studies hinted that IV has a wide range of expressivity and incomplete penetrance; that is, obligate carriers with both an affected parent and child were themselves either very mildly or not at all affected with IV.
The histology of affected areas of IV shows mild hyperkeratosis with a diminished or absent granular layer. FLG is a major component of the keratohyalin granules and is absent or markedly reduced in the skin and keratinocytes derived from IV patients (Sybert et al., 1985) . Keratins are bundled into macrofibrils through their association with FLG while the cornified envelope is being assembled and cross-linked by the transglutaminase enzyme to form the epidermal barrier. IV patients have been shown to have a mildly impaired epidermal permeability barrier or barrier recovery. So, why not close the case and declare defects in FLG to be the cause of IV? First, the decreased level of FLG may have resulted from an altered cell fate of the epidermis. Basically, if IV patients have an attenuated granular layer and granular cells synthesize FLG, then of course IV patients will have decreased FLG protein. As for the genetic studies, linkage to the EDC on 1q21 shows association with FLG and approximately 30 other genes that also play an important role in either forming or regulating the barrier. As well, one could imagine that the cause of IV was a mutation in a regulatory sequence that determined a stress response rather than a null or missense mutation in coding sequence.
The delay in finding the mutations in FLG that underlie IV is due to the unusual structure of the FLG gene. FLG is an enormously large transcript encoded by three exons. Exon 1 (15 bp) encodes only untranslated sequence. Exon 2 (159 bp) contains the translation initiation codon. Exon 3 is 12-14 kb, depending on the individual, and encodes the N-terminal portion of the protein and repeated copies of an approximately 1-kb sequence that encode the proteolytically cleaved portions of FLG. A 12-kb exon would always be tricky to amplify, but the added difficulty is that this exon cannot be amplified in sections, as it primarily contains an identical sequence repeated 10-12 times. It seems that the few specific bases that were found in the FLG repeats, which might have been used to anchor primers, often turned out to be polymorphisms between individuals. Ultimately, Smith, McLean, and colleagues (Smith et al., 2006) relied on the experience they had gained 10 years earlier while sequencing the terminal exon of the plectin gene, which similarly consists of approximately 1-kb repeats, to sequence FLG's entire terminal exon. Retaining the register of the repeats and not merely resequencing the same repeat ten times was a challenge overcome by long-range sequencing and multiple alignments.
To determine whether mutations in FLG underlie IV, Smith, McLean, and colleagues (Smith et al., 2006) sequenced the gene in a family with strong linkage to 1q21, seven unrelated IV families, and eight additional sporadic cases. Ultimately, they found two mutations in the first repeat domain of FLG: R501X and 2282del4. Both of these mutations create stop codons in the first repeat, resulting in no proteolytically processed FLG. Remarkably, these mutations were found at a combined allele frequency of approximately 4% among populations of European ancestry. This translates into one in 25 individuals being heterozygous and one in 2,500 being homozygous for FLG mutations. Genetic analysis of the pedigrees supported a semidominant mode of inheritance, as all severely affected IV patients are homozygous for FLG mutations and all mildly affected IV patients are heterozygous for FLG mutations. Interestingly, two heterozygous patients appear unaffected, reinforcing the original concept that IV has incomplete penetrance. Finally, immunohistochemical staining indicated that the proteolytically processed FLG repeats are absent from a severely affected IV patient, homozygous for FLG mutations. However, the N-terminal portion of FLG is still expressed, albeit at a lower level with patchy staining.
One feature of genes in the EDC is that all or almost all of the coding sequence is contained in the terminal exon. FLG is a founding member of the now expanded family of EDC genes that encode "fused" S100 proteins (Huber et al., 2005) . These proteins contain calcium-binding hands of the S100 type and internal tandem repeats characteristic of cornified envelope precursor proteins. In addition to FLG, the fused proteins include filaggrin 2, trichohyalin, trichohyalin 2, repetin, cornulin, and hornerin. These proteins are associated with the keratin intermediate filaments and partially cross-linked to the cornified envelope. These fused S100 proteins have two tiny exons and a large terminal coding exon. For other EDC genes, such as late cornified envelope and small proline-rich genes, loricrin, and involucrin, there is only a tiny first | All severely affected IV patients are homozygous for FLG mutations and all mildly affected IV patients are heterozygous for FLG mutations.
non-coding exon and then a large coding second exon. One explanation for the large terminal exon is that the encoded repeats have been "recently" created by unequal crossing over or gene conversion, which constrains them to one exon. Alternatively, there may be an evolutionary advantage to maintaining the coding sequence of these proteins in the terminal exons. Splicing of an intron has been shown to increase mRNA stability, with the assumption that the cell uses this to distinguish a bona fide gene from a pseudogene. However, if a termination codon is detected while the mRNA is still being spliced (that is, in any exon more than 50 bp from the terminal exon), then the mRNA is subject to nonsense-mediated decay, presumably to protect against the creation of truncated proteins with dominant-negative activity. Genes expressed from the EDC are unique in that the proteins they encode are typically expressed only as the cell is terminally differentiating and becoming enucleated. EDC proteins are substrates for the transglutaminase enzyme, which cross-links the cornified envelope. A chimeric protein might still have some biological function as a partial substrate for the transglutaminase enzyme.
The mutations identified in these IV patients are both in the first FLG repeat. It will be interesting to see whether additional mutations are identified in more terminal repeats that would still result in the expression of some FLG fragments. Obviously, being homozygous for the mutation is more deleterious than being heterozygous, so there is some advantage to attaining expression of FLG fragments. Conversely, both of these mutations occur after the sequences that encode the N-terminal fragment of FLG. The immunohistochemical data suggest that processing of FLG may still occur to produce this N-terminal fragment. Previous reports have shown that the N-terminal S100-like calcium-binding domain of FLG enters the nucleus, where it may have a role in regulating terminal differentiation (Pearton et al., 2002) . So, would a null allele of FLG that did not express the Nterminal domain have an even more severe phenotype?
Why do the R501X and 2282del4 mutations in FLG not result in a more severe phenotype? Although the other fused S100 proteins have unique expression patterns under homeostatic conditions, are they upregulated to compensate for the loss of proteolytically processed FLG repeats? Does the level of the other fused S100 proteins correlate with the phenotypic severity to explain the range of penetrance and expressivity observed with IV? One example of this is the barrier acquisition defect in utero of loricrin-deficient mice, which is rescued by compensatory upregulation of other EDC proteins (Koch et al., 2000) . Will all patients with IV turn out to have mutations in FLG? Or will there be underlying genetic diversity in the spectrum of proteins that can result in IV when mutated? Does the spontaneously occurring mouse mutant flaky tail, which has strong genetic linkage to the EDC and shows histologic features of IV, have a mutation in the Flg gene (Presland et al., 2000) ? Will haired mice be suitable animal models for adult human skin disorders, such as IV? And finally: With a carrier frequency of 4%, this is one of the most common genetic disorders. Why has a mutation that results in impaired barrier or barrier recovery become fixed in the European population? Could there be some evolutionary advantage to having a mildly impaired barrier?
In conclusion, the discovery that common mutations in FLG underlie the common skin disorder ichthyosis vulgaris answers many questions and raises as many more. Are there more secrets locked inside the EDC? Will we discover mechanisms that coordinate gene regulation in the EDC under homeostatic or stressed conditions? One more secret has been yielded. Psoriasis and atopic dermatitis both show genetic linkage to the EDC. In a commentary accompanying this one, Irvine and Irwin McLean (2006) explain that these same common mutations in FLG are a major predisposing factor for atopic dermatitis (Palmer et al., 2006) .
